The U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain.
Weekly newsletter on the latest socio-economic and political developments in Denmark and European Union
Contact us: lastweekdk@gmail.com
© Last Week in Denmark | All rights reserved
